Clinical trials showed that inhibitors of MEK1/2, downstream of the RAS pathway, had promising efficiency in KRAS mutant NSCLC and NRAS mutant melanoma [30, 31]. This evidence concerns the gene KRAS and non-small cell lung carcinoma.